CA3065240C - Transdermal therapeutic system for administering an active substance - Google Patents

Transdermal therapeutic system for administering an active substance Download PDF

Info

Publication number
CA3065240C
CA3065240C CA3065240A CA3065240A CA3065240C CA 3065240 C CA3065240 C CA 3065240C CA 3065240 A CA3065240 A CA 3065240A CA 3065240 A CA3065240 A CA 3065240A CA 3065240 C CA3065240 C CA 3065240C
Authority
CA
Canada
Prior art keywords
active substance
layer
therapeutic system
transdermal therapeutic
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3065240A
Other languages
English (en)
French (fr)
Other versions
CA3065240A1 (en
Inventor
Britta Langer
Bjoern Schurad
Heike Prinz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luye Pharma AG
Original Assignee
Luye Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luye Pharma AG filed Critical Luye Pharma AG
Publication of CA3065240A1 publication Critical patent/CA3065240A1/en
Application granted granted Critical
Publication of CA3065240C publication Critical patent/CA3065240C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3065240A 2010-12-14 2011-12-14 Transdermal therapeutic system for administering an active substance Active CA3065240C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10194968.3A EP2468274B1 (de) 2010-12-14 2010-12-14 Transdermales therapeutisches System zur Verabreichung eines Wirkstoffs
EP10194968.3 2010-12-14
CA2817461A CA2817461C (en) 2010-12-14 2011-12-14 Transdermal therapeutic system for administering an active substance

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2817461A Division CA2817461C (en) 2010-12-14 2011-12-14 Transdermal therapeutic system for administering an active substance

Publications (2)

Publication Number Publication Date
CA3065240A1 CA3065240A1 (en) 2012-06-21
CA3065240C true CA3065240C (en) 2022-02-15

Family

ID=43836835

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3065240A Active CA3065240C (en) 2010-12-14 2011-12-14 Transdermal therapeutic system for administering an active substance
CA2817461A Active CA2817461C (en) 2010-12-14 2011-12-14 Transdermal therapeutic system for administering an active substance

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2817461A Active CA2817461C (en) 2010-12-14 2011-12-14 Transdermal therapeutic system for administering an active substance

Country Status (25)

Country Link
US (2) US10660863B2 (enExample)
EP (2) EP2468274B1 (enExample)
JP (1) JP6043296B2 (enExample)
KR (1) KR101842309B1 (enExample)
CN (3) CN107412202A (enExample)
AU (2) AU2011343363B2 (enExample)
BR (1) BR112013014616B1 (enExample)
CA (2) CA3065240C (enExample)
CY (2) CY1116638T1 (enExample)
DK (2) DK2468274T3 (enExample)
EA (1) EA026520B1 (enExample)
ES (2) ES2545094T3 (enExample)
HK (1) HK1243336A1 (enExample)
HR (2) HRP20201880T1 (enExample)
HU (2) HUE027916T2 (enExample)
LT (1) LT2651410T (enExample)
MX (1) MX345344B (enExample)
MY (1) MY183873A (enExample)
PL (2) PL2468274T3 (enExample)
PT (2) PT2468274E (enExample)
RS (2) RS54173B1 (enExample)
SI (2) SI2468274T1 (enExample)
SM (2) SMT202000638T1 (enExample)
WO (1) WO2012080365A1 (enExample)
ZA (1) ZA201303965B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012000369A1 (de) * 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
DE102012016317A1 (de) * 2012-08-14 2014-02-20 Jenabatteries GmbH Redox-Flow-Zelle zur Speicherung elektrischer Energie
US20150196515A1 (en) * 2012-08-15 2015-07-16 Dow Coming Corporation Multi-Layer Drug Delivery System
WO2014111790A2 (en) * 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
US20240082065A1 (en) * 2016-07-08 2024-03-14 Moteah Williams Waterproof and transparent wound barrier and method of manufacturing same
JP6864968B2 (ja) 2016-08-22 2021-04-28 救急薬品工業株式会社 貼付剤
JP7193863B2 (ja) * 2017-07-19 2022-12-21 帝國製薬株式会社 リバスチグミン含有経皮吸収型製剤
DE102018120505A1 (de) * 2017-10-20 2019-04-25 Amw Gmbh Verhinderung der Kristallisation von Wirkstoffen in transdermalen Darreichungssystemen
DE102017127433A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS auf Basis von klebenden Weichmacher-Polymer-Matrices
EP3764998A1 (en) * 2018-03-13 2021-01-20 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
WO2019220697A1 (ja) * 2018-05-17 2019-11-21 パナソニックＩｐマネジメント株式会社 生体貼付け用選択透過膜、経皮吸収キットおよび美容方法
ES2923891T3 (es) 2018-08-08 2022-10-03 Danapak Flexibles As Películas y láminas mejoradas para usarse en el envase de compuestos reactivos
KR102823139B1 (ko) 2018-08-31 2025-06-19 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102710072B1 (ko) 2018-08-31 2024-09-24 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
CA3146086A1 (en) * 2019-07-09 2021-01-14 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising an active agent-containing layer comprising an acrylic polymer and a skin contact layer comprising a silicone gel adhesive
CN113616625B (zh) * 2021-08-26 2023-05-30 大连科翔科技开发有限公司 一种卡巴拉汀的长效透皮贴剂
DE102021128912A1 (de) * 2021-11-05 2023-05-11 Lts Lohmann Therapie-Systeme Ag. Okklusives pflaster mit flexibler backing

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
KR950702811A (ko) * 1992-08-25 1995-08-23 더블유. 클레어리 게리 프린트 경피약제투여장치(Printed Transdermal Drug Delivery Device)
JPH0912448A (ja) * 1995-04-28 1997-01-14 Read Chem Kk 薬物放出制御型経皮吸収製剤
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6348210B1 (en) * 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
DE19918106A1 (de) * 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
DE10103860B4 (de) * 2001-01-30 2004-12-23 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Verabreichung carboxylgruppenhaltiger, nichtsteroidaler Antiphlogistika, sowie Verfahren zu seiner Herstellung
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
DE10141652B4 (de) 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE602005021909D1 (de) * 2004-10-21 2010-07-29 Durect Corp Transdermale verabreichungssysteme
US8252319B2 (en) * 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
US7943812B2 (en) * 2005-12-30 2011-05-17 Colopast A/S Layered adhesive construct having a mouldable layer as skin contact surface
CN101304735A (zh) * 2006-01-12 2008-11-12 Lts勒曼治疗系统股份公司 用于挥发性和/或热不稳定的物质的经皮治疗体系
WO2007129427A1 (ja) 2006-05-08 2007-11-15 Teikoku Seiyaku Co., Ltd. 抗認知症薬物の経皮吸収製剤
US9248104B2 (en) * 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
WO2009009651A1 (en) * 2007-07-10 2009-01-15 Agile Therapeutics, Inc. Dermal delivery device with ultrasonic weld
WO2009026135A2 (en) 2007-08-17 2009-02-26 Alza Corporation Controlled transdermal bisoprolol delivery system
ES2661767T3 (es) * 2008-02-27 2018-04-03 Hisamitsu Pharmaceutical Co., Inc. Parche adhesivo para la piel y producto envasado
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
JP2010126450A (ja) * 2008-11-25 2010-06-10 Lintec Corp 経皮吸収貼付剤
CN102711744B (zh) * 2009-12-22 2014-06-25 阿西诺股份公司 用于施用利凡斯的明和其衍生物的透皮治疗系统

Also Published As

Publication number Publication date
SI2468274T1 (sl) 2015-10-30
HUE027916T2 (en) 2016-11-28
BR112013014616B1 (pt) 2021-12-21
ES2836483T3 (es) 2021-06-25
EA201300704A1 (ru) 2014-01-30
LT2651410T (lt) 2020-12-28
AU2011343363B2 (en) 2017-06-08
US20140323996A1 (en) 2014-10-30
AU2017213569A1 (en) 2017-08-31
HRP20150881T1 (hr) 2015-09-25
AU2017213569B2 (en) 2019-04-11
KR20130129988A (ko) 2013-11-29
SMT201500184B (it) 2015-09-07
CA2817461A1 (en) 2012-06-21
RS54173B1 (sr) 2015-12-31
HRP20201880T1 (hr) 2021-02-05
HK1243336A1 (zh) 2018-07-13
CY1123712T1 (el) 2022-03-24
CN103269698A (zh) 2013-08-28
US10660863B2 (en) 2020-05-26
DK2468274T3 (en) 2015-08-31
JP6043296B2 (ja) 2016-12-14
ZA201303965B (en) 2014-09-25
PL2468274T3 (pl) 2015-11-30
PT2468274E (pt) 2015-09-21
EP2468274B1 (de) 2015-07-01
CN107412202A (zh) 2017-12-01
EP2651410A1 (de) 2013-10-23
CA2817461C (en) 2020-02-25
RS61155B1 (sr) 2020-12-31
JP2014503523A (ja) 2014-02-13
MY183873A (en) 2021-03-17
CY1116638T1 (el) 2017-03-15
CN103269698B (zh) 2017-07-14
KR101842309B1 (ko) 2018-03-26
MX345344B (es) 2017-01-26
PT2651410T (pt) 2020-12-15
SI2651410T1 (sl) 2021-01-29
SMT202000638T1 (it) 2021-01-05
DK2651410T3 (da) 2020-11-02
ES2545094T3 (es) 2015-09-08
PL2651410T3 (pl) 2021-03-08
MX2013005581A (es) 2013-08-26
EP2468274A1 (de) 2012-06-27
WO2012080365A1 (de) 2012-06-21
EP2651410B1 (de) 2020-10-14
CA3065240A1 (en) 2012-06-21
CN113244199A (zh) 2021-08-13
AU2011343363A1 (en) 2013-06-20
EA026520B1 (ru) 2017-04-28
BR112013014616A2 (pt) 2016-09-20
HUE052137T2 (hu) 2021-04-28
US20200289426A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
CA3065240C (en) Transdermal therapeutic system for administering an active substance
KR101674240B1 (ko) 리바스티그민 또는 그의 유도체 투여용 경피 치료 시스템
US10076502B2 (en) Transdermal therapeutic system for administering rivastigmine or derivatives thereof
HK1187247B (en) Transdermal therapeutic system for administering an active substance
HK1187247A (en) Transdermal therapeutic system for administering an active substance
HK1170945A (en) Transdermal therapeutic system for administering rivastigmine or derivatives thereof
HK1170945B (en) Transdermal therapeutic system for administering rivastigmine or derivatives thereof
AU2013242824A1 (en) Transdermal therapeutic system for administration of fentanyl or an analog thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191213

EEER Examination request

Effective date: 20191213